State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.

[1]  Graham F. Medley,et al.  Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control , 2001, Nature Medicine.

[2]  Carl T. Bergstrom,et al.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Arndt,et al.  The TORCH syndrome: a clinical review. , 1985, Journal of the American Academy of Dermatology.

[4]  M. Weinstein,et al.  Decision Making in Health and Medicine , 2001 .

[5]  J. Císcar,et al.  Modeling the Impact of Genetic Screening Technologies on Healthcare , 2007, Molecular Diagnosis & Therapy.

[6]  Amy B. Knudsen,et al.  Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[7]  A Jakins,et al.  The cost of hepatitis A infections in American adolescents and adults in 1997 , 2000, Hepatology.

[8]  U. Siebert,et al.  Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security , 2005, International Journal of Technology Assessment in Health Care.

[9]  Mirjam Kretzschmar,et al.  Mathematical Models in Infectious Disease Epidemiology , 2009, Modern Infectious Disease Epidemiology.

[10]  M. Lipsitch.  Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. , 1999, Emerging infectious diseases.

[11]  Annika Tiveljung-Lindell,et al.  High Occurrence of a New Variant of Chlamydia trachomatis Escaping Diagnostic Tests Among STI Clinic Patients in Stockholm, Sweden , 2008, Sexually transmitted diseases.

[12]  Timothy C. Reluga,et al.  Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum , 2007, Proceedings of the National Academy of Sciences.

[13]  M. Lipsitch,et al.  Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. , 2007, The Journal of infectious diseases.

[14]  D. Fisman,et al.  The Philadelphia High-School STD Screening Program: Key Insights From Dynamic Transmission Modeling , 2008, Sexually transmitted diseases.

[15]  W. Edmunds,et al.  Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV , 2003, Journal of medical virology.

[16]  Douglas K Owens,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.

[17]  M. Weinstein,et al.  Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. , 1997, Journal of the American College of Cardiology.

[18]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  E. Myers,et al.  Cost-effectiveness of cervical cancer screening , 2006 .

[20]  Douglas K Owens,et al.  Grading the Strength of a Body of Evidence When Comparing Medical Interventions , 2009 .

[21]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[22]  M. Weinstein,et al.  Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. , 2008, Radiology.

[23]  Claudio J. Struchiner,et al.  Design and Analysis of Vaccine Studies , 2009 .

[24]  W. Edmunds,et al.  Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination Programs , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  M. van Boven,et al.  Pathogen adaptation under imperfect vaccination: implications for pertussis , 2005, Proceedings of the Royal Society B: Biological Sciences.

[26]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[27]  W. Edmunds,et al.  The effect of vaccination on the epidemiology of varicella zoster virus. , 2002, The Journal of infection.

[28]  J. Giesecke,et al.  Modern Infectious Disease Epidemiology , 1994 .

[29]  E. Myers,et al.  Chapter 19: Cost-effectiveness of cervical cancer screening. , 2006, Vaccine.

[30]  P Barton,et al.  Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling , 2006, Sexually Transmitted Infections.

[31]  M. Jit,et al.  Modelling the Epidemiology of Infectious Diseases for Decision Analysis , 2011, PharmacoEconomics.

[32]  J. Douglas Faires,et al.  Numerical Analysis , 1981 .

[33]  Gregory S Zaric,et al.  The Impact of Ignoring Population Heterogeneity when Markov Models are Used in Cost-Effectiveness Analysis , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  Milton C. Weinstein,et al.  Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.

[35]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  R. Brunham,et al.  The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. , 2005, The Journal of infectious diseases.

[37]  Douglas K Owens,et al.  Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.

[38]  Maria Pia Saccomani,et al.  An Effective Automatic Procedure for Testing Parameter Identifiability of HIV/AIDS Models , 2011, Bulletin of mathematical biology.

[39]  T. Wisløff,et al.  Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden , 2008, Scandinavian journal of infectious diseases.

[40]  Natasha K Stout,et al.  Keeping the noise down: common random numbers for disease simulation modeling , 2008, Health care management science.

[41]  Richard L. Burden,et al.  Numerical analysis: 4th ed , 1988 .

[42]  R. Reinert,et al.  Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects , 2009, The European Journal of Health Economics.

[43]  W. Edmunds,et al.  Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[44]  S. Homan,et al.  Determining Transition Probabilities , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[45]  M. Weinstein,et al.  Life Expectancy Biases in Clinical Decision Modeling , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  D. Fisman,et al.  Canada in the face of the 2009 H1N1 pandemic , 2010, Influenza and Other Respiratory Viruses.

[47]  D. Fisman,et al.  Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. , 2010, Vaccine.

[48]  T. Panagiotopoulos,et al.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. , 1999, BMJ.

[49]  C. Macken,et al.  Modeling targeted layered containment of an influenza pandemic in the United States , 2008, Proceedings of the National Academy of Sciences.

[50]  M. Jit,et al.  Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models , 2011, BMC medicine.

[51]  R. Mikolajczyk,et al.  Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases , 2008, PLoS medicine.

[52]  Joseph Lau,et al.  Decision-Analytic Modeling to Evaluate Benefits and Harms of Medical Tests: Uses and Limitations , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[53]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[54]  J. Caro,et al.  Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.

[55]  J. Robins,et al.  Transmission Dynamics and Control of Severe Acute Respiratory Syndrome , 2003, Science.

[56]  Zaid Chalabi,et al.  Dynamic Modeling of Herpes Simplex Virus Type-2 (HSV-2) Transmission: Issues in Structural Uncertainty , 2009, Bulletin of mathematical biology.

[57]  N. Osgood,et al.  Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling , 2010, BMC infectious diseases.

[58]  Sun-Young Kim,et al.  Cost-Effectiveness Analyses of Vaccination Programmes , 2012, PharmacoEconomics.

[59]  S. Pauker,et al.  Patient-specific decisions about hormone replacement therapy in postmenopausal women , 1997 .

[60]  Mirjam Kretzschmar,et al.  Costs and Effects of Chlamydial Screening: Dynamic versus Static Modeling , 2005, Sexually transmitted diseases.

[61]  F A Sonnenberg,et al.  Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.

[62]  Paul Barnett,et al.  Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules , 2003, Annals of Internal Medicine.

[63]  Ellen Brooks-Pollock,et al.  The Impact of Realistic Age Structure in Simple Models of Tuberculosis Transmission , 2010, PloS one.

[64]  S. Dewilde,et al.  The Cost-Effectiveness of Screening Programs Using Single and Multiple Birth Cohort Simulations: A Comparison Using a Model of Cervical Cancer , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[65]  Wendy Macdowall,et al.  Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours , 2001, The Lancet.

[66]  E. Zagheni,et al.  Using time-use data to parameterize models for the spread of close-contact infectious diseases. , 2008, American journal of epidemiology.

[67]  H. Houweling,et al.  Vaccins tegen Humaan papillomavirus (HPV); tussen registratie en implementatie , 2008 .

[68]  Michael L. Johnson,et al.  Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[69]  Uwe Siebert,et al.  Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retr , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[70]  A. Melegaro,et al.  The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. , 2012, Vaccine.

[71]  M. Halloran,et al.  Assessing Indirect, Total, and Overall Effects , 2010 .

[72]  Martin L. Puterman,et al.  Markov Decision Processes: Discrete Stochastic Dynamic Programming , 1994 .

[73]  G. Sanders,et al.  Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age , 2008, Annals of Internal Medicine.

[74]  Marc S. Williams,et al.  A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing , 2010, PharmacoEconomics (Auckland).

[75]  Uwe Siebert,et al.  When should decision-analytic modeling be used in the economic evaluation of health care? , 2003, The European Journal of Health Economics, formerly: HEPAC.

[76]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[77]  Douglas K Owens,et al.  AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. , 2010, Journal of clinical epidemiology.

[78]  M. Lipsitch,et al.  Vaccination against colonizing bacteria with multiple serotypes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R M May,et al.  Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes , 1985, Journal of Hygiene.

[80]  A. Flisser,et al.  Measles, rubella, and congenital rubella syndrome--United States and Mexico, 1997-1999. , 2000, MMWR. Morbidity and mortality weekly report.

[81]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[82]  E. Grill,et al.  Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis , 2005, BMC public health.

[83]  T. Jelínek.  Imported falciparum malaria in Europe: 2007 data from TropNetEurop. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[84]  Alessandro Vespignani,et al.  Comparing large-scale computational approaches to epidemic modeling: Agent-based versus structured metapopulation models , 2010, BMC infectious diseases.

[85]  David M. Eddy,et al.  Screening for cancer : theory, analysis, and design , 1984 .

[86]  M. Weinstein,et al.  Effects of Categorizing Continuous Variables in Decision-Analytic Models , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[87]  W. Edmunds,et al.  Modelling the impact of immunization on the epidemiology of varicella zoster virus , 2000, Epidemiology and Infection.

[88]  Cost-effectiveness of Breast MR Imaging and Screen-Film Mammography for Screening BRCA1 Gene Mutation Carriers , 2011 .

[89]  W. Rogowski.  The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[90]  Chris Hyde,et al.  Decision Making in Health and Medicine. Integrating Evidence and Values , 2005, ACP Journal Club.

[91]  C. Fraser,et al.  Factors that make an infectious disease outbreak controllable. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Mirjam Kretzschmar,et al.  Dynamic Transmission Modeling , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[93]  J. Caro,et al.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[94]  Karen M Kuntz,et al.  Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. , 2011, AJR. American journal of roentgenology.

[95]  M G Myriam Hunink,et al.  Uncertainty and Patient Heterogeneity in Medical Decision Models , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[96]  Martin Spielauer,et al.  Dynamic microsimulation of health care demand, health care finance and the economic impact of health behaviours: survey and review , 2007 .

[97]  Matthew H Samore,et al.  Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. , 2006, American journal of epidemiology.

[98]  L. Russell,et al.  Reviews and Notes: Educated Guesses: Making Policy about Medical Screening Tests , 1994, Annals of Internal Medicine.

[99]  Murray Krahn,et al.  Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[100]  D J Nokes,et al.  Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. , 1999, Statistics in medicine.

[101]  K. Kuntz,et al.  Assessing the Sensitivity of Decision-Analytic Results to Unobserved Markers of Risk: Defining the Effects of Heterogeneity Bias , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[102]  Mirjam Kretzschmar,et al.  The role of reinfection and partner notification in the efficacy of Chlamydia screening programs. , 2011, The Journal of infectious diseases.

[103]  D. Fisman,et al.  Modelling an influenza pandemic: A guide for the perplexed , 2009, Canadian Medical Association Journal.

[104]  M. Boily,et al.  Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. , 2010, Vaccine.

[105]  Anne M Johnson,et al.  Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection , 2001, The Lancet.

[106]  R. Holman,et al.  A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.

[107]  M G Hunink,et al.  Noninvasive Imaging for the Diagnosis of Coronary Artery Disease: Focusing the Development of New Diagnostic Technology , 1999, Annals of Internal Medicine.

[108]  Ameet Bakhai,et al.  Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial , 2004, Circulation.

[109]  Uwe Siebert,et al.  Effects of multiple interventions , 2004 .

[110]  S. Lindsay,et al.  Assessing the future threat from vivax malaria in the United Kingdom using two markedly different modelling approaches , 2010, Malaria Journal.

[111]  Liliana Perez,et al.  An agent-based approach for modeling dynamics of contagious disease spread , 2009, International journal of health geographics.

[112]  R. Hutubessy,et al.  Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal , 2011, BMC medicine.

[113]  Oguzhan Alagoz,et al.  Markov Decision Processes: A Tool for Sequential Decision Making under Uncertainty , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[114]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[115]  Mirjam Kretzschmar,et al.  Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 , 2012, Value in Health.

[116]  K. Kelikowske.  Educated Guesses: Making Policy about Medical Screening Tests , 1994 .

[117]  W. Edmunds,et al.  Varicella vaccine and shingles. , 2002 .

[118]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[119]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[120]  Jonathan Karnon,et al.  Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[121]  P. Hillemanns,et al.  Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis. , 2011, European journal of cancer.

[122]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[123]  Paul A Scuffham,et al.  Funding of drugs: do vaccines warrant a different approach? , 2008, The Lancet Infectious Diseases.